Differential regulation of glutamate receptors in Alzheimer's disease

NeuroSignals

Volumn 11, Issue 5, 2002, Pages 282-292

  Lee, Hyoung Gon ^a   Zhu, Xiongwei ^a   Ghanbari, Hossein A ^b   Ogawa, Osamu ^a   Raina, Arun K ^a   O'Neill, Micheal J ^c   Perry, George ^a   Smith, Mark A ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Panacea Pharmaceuticals   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Alzheimer's disease; Glutamate receptor; Neuropathology

Indexed keywords

AMPA RECEPTOR; KAINIC ACID RECEPTOR; METABOTROPIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; GLUTAMATE RECEPTOR;

ALZHEIMER DISEASE; DISEASE SEVERITY; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LIGAND BINDING; LONG TERM POTENTIATION; MEDICAL ASSESSMENT; NERVE CELL NECROSIS; NERVE CELL PLASTICITY; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NEUROTOXICITY; NEUROTRANSMISSION; PARKINSON DISEASE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS REGULATION; REVIEW; WESTERN BLOTTING; ANIMAL; BIOLOGICAL MODEL; BRAIN; DEGENERATIVE DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; BRAIN; HUMANS; MODELS, NEUROLOGICAL; NEURODEGENERATIVE DISEASES; RECEPTORS, GLUTAMATE; RECEPTORS, KAINIC ACID; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0036769255     PISSN: 1424862X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000067427     Document Type: Review

References (128)

1. Smith MA: Alzheimer disease. Int Rev Neurobiol 1998;42:1-54.
2. McShea A, Zelasko DA, Gerst JL, Smith MA: Signal transduction abnormalities in Alzheimer's disease: Evidence of a pathogenic stimuli. Brain Res 1999;815:237-242.
3. Perry G, Roder H, Nunomura A, et al: Activation of neuronal extracellular receptor kinase (ERK) in Alzheimer disease links oxidative stress to abnormal phosphorylation. Neuroreport 1999;10:2411-2415.
4. Zhu X, Rottkamp CA, Hartzler A, et al: Activation of MKK6, an upstream activator of p38, in Alzheimer's disease. J Neurochem 2001;79:311-318.
5. Francis PT, Sims NR, Procter AW, Bowen DM: Cortical pyramidal neuron loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease: Investigative and therapeutic perspectives. J Neurochem 1993;60:1589-1604.
6. Beal MF: Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol 1992;31:119-130.
7. Esclaire F, Lesort M, Blanchard C, Hugon J: Glutamate toxicity enhances tau gene expression in neuronal cultures. J Neurosci Res 1997;49:309-318.
8. Couratier P, Lesort M, Sindou P, Esclaire F, Yardin C, Hugon J: Modifications of neuronal phosphorylated tau immunoreactivity induced by NMDA toxicity. Mol Chem Neuropathol 1996;27:259-273.
9. Couratier P, Sindou P, Tabaraud F, Diop AG, Spencer PS, Hugon J: Modulation of tau neuronal expression induced by NMDA, non-NMDA and metabotropic glutamate receptor agonists. Neurodegeneration 1995;4:33-41.
10. Parsons C, Danysz W, Lodge D: Introduction to glutamate receptors, their function and pharmacology; in Danysz W, Lodge D, Parsons CG (eds): Ionotropic Glutamate Receptors as Therapeutic Targets. Johnson City, F.P. Graham Publishing, 2002, pp 1-30.
11. Mayer ML, Westbrook GL: The physiology of excitatory amino acids in the vertebrate central nervous system. Prog Neurobiol 1987;28:197-276.
12. Monaghan DT, Bridges RJ, Cotman CW: The excitatory amino acid receptors: Their classes, pharmacology, and distinct properties in the function of the central nervous system. Annu Rev Pharmacol Toxicol 1989;29:365-402.
13. Nakazawa K, Quirk MC, Chitwood RA, et al: Requirement for hippocampal CA3 NMDA receptors in associative memory recall. Science 2002;297:211-218.
14. Clayton DA, Mesches MH, Alvarez E, Bickford PC, Browning MD: A hippocampal NR2B deficit can mimic age-related changes in long-term potentiation and spatial learning in the Fischer 344 rat. J Neurosci 2002;22:3628-3637.
15. Hampson RE, Rogers G, Lynch G, Deadwyler SA: Facilitative effects of the ampakine CX516 on short-term memory in rats: Correlations with hippocampal neuronal activity. J Neurosci 1998;18:2748-2763.
16. Hampson RE, Rogers G, Lynch G, Deadwyler SA: Facilitative effects of the ampakine CX516 on short-term memory in rats: Enhancement of delayed-nonmatch-to- sample performance. J Neurosci 1998;18:2740-2747.
17. Lynch G: Memory and the Brain: Unexpected Chemistries and a New Pharmacology. Neurobiol Learn Mem 1998;70:82-100.
18. Hayashi T, Umemori H, Mishina M, Yamamoto T: The AMPA receptor interacts with and signals through the protein tyrosine kinase Lyn. Nature 1999;397:72-76.
19. Lauterborn JC, Lynch G, Vanderklish P, Arai A, Gall CM: Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons. J Neurosci 2000;20:8-21.
20. Mackowiak M, O'Neill MJ, Hicks CA, Bleakman D, Skolnick P: An AMPA receptor potentiator modulates the expression of BDNF: An in vivo study. Neuropharmacology 2002;43:1-10.
21. Choi DW, Rothman SM: The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu Rev Neurosci 1990;13:171-182.
22. Meldrum B, Garthwaite J: Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci 1990;11:379-387.
23. Doble A: The role of excitotoxicity in neurodegenerative disease: Implications for therapy. Pharmacol Ther 1999;81:163-221.
24. Ozawa S, Kamiya H, Tsuzuki K: Glutamate receptors in the mammalian central nervous system. Prog Neurobiol 1998;54:581-618.
25. Choi DW: Excitotoxic cell death. J Neurobiol 1992;23:1261-1276.
26. Choi DW: Ionic dependence of glutamate neurotoxicity. J Neurosci 1987;7:369-379.
27. Lodge D, Dingledine R: Ionotropic glutamate receptors; in The IUPHAR Compendium of Receptor Characterization and Classification. London, IUPHAR Media, 2000.
28. Lynch DR, Guttmann RP: Excitotoxicity: Perspectives based on N-methyl-D-aspartate receptor subtypes. J Pharmacol Exp Ther 2002; 300:717-723.
29. Nakanishi S: Molecular diversity of glutamate receptors and implications for brain function. Science 1992;258:597-603.
30. Mori H, Mishina M: Structure and function of the NMDA receptor channel. Neuropharmacology 1995;34:1219-1237.
31. Morris RG, Anderson E, Lynch GS, Baudry M: Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature 1986;319:774-776.
32. Choi DW: Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988;1: 623-634.
33. O'Neill MJ, Lees K: Effects of ionotropic glutamate antagonists in stroke; in Danysz W, Lodge D, Parsons CG (eds): Ionotropic Glutamate Receptors as Therapeutic Targets. Johnson City, F.P. Graham Publishing, 2002, pp 403-447.
34. Iino M, Ozawa S, Tsuzuki K: Permeation of calcium through excitatory amino acid receptor channels in cultured rat hippocampal neurones. J Physiol 1990;424:151-165.
35. Bleakman D, Lodge D: Neuropharmacology of AMPA and kainate receptors. Neuropharmacology 1998;37:1187-1204.
36. Lodge D, Bond A, O'Neill MJ, Hicks CA, Jones MG: Stereoselective effects-of 2,3-benzodiazepines in vivo: Electrophysiology and neuroprotection studies. Neuropharmacology 1996;35:1681-1688.
37. Bleakman D, Ballyk BA, Schoepp DD, et al: Activity of 2, 3-benzodiazepines at native rat and recombinant human glutamate receptors in vitro: Stereospecificity and selectivity profiles. Neuropharmacology 1996;35:1689-1702.
38. Bettler B, Mulle C: Review: Neurotransmitter receptors. II. AMPA and kainate receptors. Neuropharmacology 1995;34:123-139.
39. O'Neill MJ, Bond A, Ornstein PL, et al: Decahydroisoquinolines: Novel competitive AMPA/kainate antagonists with neuroprotective effects in global cerebral ischaemia. Neuropharmacology 1998;37:1211-1222.
40. Clarke VR, Ballyk BA, Hoo KH, et al: A hippocampal GluR5 kainate receptor regulating inhibitory synaptic transmission. Nature 1997;389:599-603.
41. O'Neill MJ, Bogaert L, Hicks CA, et al: LY377770, a novel iGlu5 kainate receptor antagonist with neuroprotective effects in global and focal cerebral ischaemia. Neuropharmacology 2000;39:1575-1588.
42. Smolders I, Bortolotto ZA, Clarke VR, et al: Antagonists of GLU(K5)-containing kainate receptors prevent pilocarpine-induced limbic seizures. Nat Neurosci 2002;5:796-804.
43. Pin JP, De Colle C, Bessis AS, Acher F: New perspectives for the development of selective metabotropic glutamate receptor ligands. Eur J Pharmacol 1999;375:277-294.
44. Pin JP, Duvoisin R: The metabotropic glutamate receptors: Structure and functions. Neuropharmacology 1995;34:1-26.
45. Schoepp DD, Jane DE, Monn JA: Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 1999;38:1431-1476.
46. Chuang SC, Bianchi R, Wong RK: Group I mGluR activation turns on a voltage-gated inward current in hippocampal pyramidal cells. J Neurophysiol 2000;83:2844-2853.
47. Shigemoto R, Kinoshita A, Wada E, et al: Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus. J Neurosci 1997;17:7503-7522.
48. Ferraguti F, Baldani-Guerra B, Corsi M, Na-kanishi S, Corti C: Activation of the extracellu-lar signal-regulated kinase 2 by metabotropic glutamate receptors. Eur J Neurosci 1999;11: 2073-2082.
49. Phillips T, Barnes A, Scott S, Emson P, Rees S: Human metabotropic glutamate receptor 2 couples to the MAP kinase cascade in Chinese hamster ovary cells. Neuroreport 1998;9:2335-2339.
50. Kingston AE, O'Neill MJ, Lam A, Bales KR, Monn JA, Schoepp DD: Neuroprotection by metabotropic glutamate receptor glutamate receptor agonists: LY354740, LY379268 and LY389795. Eur J Pharmacol 1999;377:155-165.
51. Bond A, Jones NM, Hicks CA, et al: Neuropro-tective effects of LY379268, a selective mGlu2/3 receptor agonist: Investigations into possible mechanism of action in vivo. J Pharmacol Exp Ther 2000;294:800-809.
52. Cartmell J, Monn JA, Schoepp DD: Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine. Psychopharmacology (Berl) 2000;148:423-429.
53. Bruno V, Battaglia G, Copani A, et al: Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs. J Cereb Blood Flow Metab 2001;21:1013-1033.
54. Iacovelli L, Bruno V, Salvatore L, et al: Native group-III metabotropic glutamate receptors are coupled to the mitogen-activated protein kinase/phosphatidylinositol-3-kinase pathways. J Neurochem 2002;82:216-223.
55. Ikonomovic MD, Mizukami K, Warde D, et al: Distribution of glutamate receptor subunit NMDAR1 in the hippocampus of normal elderly and patients with Alzheimer's disease. Exp Neurol 1999;160:194-204.
56. Hynd MR, Scott HL, Dodd PR: Glutamate(NMDA) receptor NR1 subunit mRNA expression in Alzheimer's disease. J Neurochem 2001;78:175-182.
57. Sze C, Bi H, Kleinschmidt-DeMasters BK, Filley CM, Martin LJ: N-Methyl-D-aspartate receptor subunit proteins and their phosphorylation status are altered selectively in Alzheimer's disease. J Neurol Sci 2001;182:151-159.
58. Ulas J, Cotman CW: Decreased expression of N-methyl-D-aspartate receptor 1 messenger RNA in select regions of Alzheimer brain. Neuroscience 1997;79:973-982.
59. Panegyres PK, Zafiris-Toufexis K, Kakulas BA: The mRNA of the NR1 subtype of glutamate receptor in Alzheimer's disease. J Neural Transm 2002;109:77-89.
60. Bi H, Sze CI: N-methyl-D-aspartate receptor subunit NR2A and NR2B messenger RNA levels are altered in the hippocampus and entorhinal cortex in Alzheimer's disease. J Neurol Sci 2002;200:11-18.
61. Wakabayashi K, Narisawa-Saito M, Iwakura Y, et al: Phenotypic down-regulation of glutamate receptor subunit GluR1 in Alzheimer's disease. Neurobiol Aging 1999;20:287-295.
62. Thorns V, Mallory M, Hansen L, Masliah E: Alterations in glutamate receptor 2/3 subunits and amyloid precursor protein expression during the course of Alzheimer's disease and Lewy body variant. Acta Neuropathol (Berl) 1997;94:539-548.
63. Cowburn R, Hardy J, Roberts P, Briggs R: Regional distribution of pre- and postsynaptic glutamatergic function in Alzheimer's disease. Brain Res 1988;452:403-407.
64. Del Bel EA, Slater P: Binding to the glycine site of the NMDA receptor complex in brains of patients with Alzheimer's disease. Neurosci Lett 1991;131:75-78.
65. Carlson MD, Penney JB Jr, Young AB: NMDA, AMPA, and benzodiazepine binding site changes in Alzheimer's disease visual cortex. Neurobiol Aging 1993;14:343-352.
66. 3H]glutamate binding. J Neurochem 1987;48:543-551.
67. Penney JB, Maragos WF, Greenamyre JT, Debowey DL, Hollingsworth Z, Young AB: Excitatory amino acid binding sites in the hippocampal region of Alzheimer's disease and other dementias. J Neurol Neurosurg Psychiatry 1990;53:314-320.
68. Cowburn R, Hardy J, Roberts P, Briggs R: Presynaptic and postsynaptic glutamatergic function in Alzheimer's disease. Neurosci Lett 1988;86:109-113.
69. Geddes JW, Cotman CW: Plasticity in hippocampal excitatory amino acid receptors in Alzheimer's disease. Neurosci Res 1986;3:672-678.
70. 3H]CPP): Receptor status in Alzheimer's disease brains. Eur J Pharmacol 1992;225:195-201.
71. Porter RH, Roberts PJ, Briggs RS: NMDA receptor status in elderly normal individuals and those with Alzheimer's disease. Ann NY Acad Sci 1993;695:50-53.
72. Ulas J, Weihmuller FB, Brunner LC, Joyce JN, Marshall JF, Cotman CW: Selective increase of NMDA-sensitive glutamate binding in the striatum of Parkinson's disease, Alzheimer's disease, and mixed Parkinson's disease/Alzheimer's disease patients: An autoradiographic study. J Neurosci 1994;14:6317-6324.
73. Castellano C, Cestari V, Ciamei A: NMDA receptors and learning and memory processes. Curr Drug Targets 2001;2:273-283.
74. Kuiper MA, Teerlink T, Visser JJ, Bergmans PL, Scheltens P, Wolters EC: L-Glutamate, L-arginine and L-citrulline levels in cerebrospinal fluid of Parkinson's disease, multiple system atrophy, and Alzheimer's disease patients. J Neural Transm 2000;107:183-189.
75. Hyman BT, Van Hoesen GW, Damasio AR: Alzheimer's disease: Glutamate depletion in the hippocampal perforant pathway zone. Ann Neurol 1987;22:37-40.
76. Weiss JH, Yin HZ, Choi DW: Basal forebrain cholinergic neurons are selectively vulnerable to AMPA/kainate receptor-mediated neurotoxicity. Neuroscience 1994;60:659-664.
77. Page KJ, Everitt BJ, Robbins TW, Marston HM, Wilkinson LS: Dissociable effects on spatial maze and passive avoidance acquisition and retention following AMPA- and ibotenic acid-induced excitotoxic lesions of the basal forebrain in rats: Differential dependence on cholinergic neuronal loss. Neuroscience 1991;43:457-472.
78. Ikonomovic MD, Sheffield R, Armstrong DM: AMPA-selective glutamate receptor subtype immunoreactivity in the hippocampal formation of patients with Alzheimer's disease. Hippocampus 1995;5:469-486.
79. Armstrong DM, Ikonomovic MD, Sheffield R, Wenthold RJ: AMPA-selective glutamate receptor subtype immunoreactivity in the entorhinal cortex of non-demented elderly and patients with Alzheimer's disease. Brain Res 1994;639:207-216.
80. Dewar D, Chalmers DT, Graham DI, McCul-loch J: Glutamate metabotropic and AMPA binding sites are reduced in Alzheimer's disease: An autoradiographic study of the hippocampus. Brain Res 1991;553:58-64.
81. Dewar D, Chalmers DT, Shand A, Graham DI, McCulloch J: Selective reduction of quisqualate (AMPA) receptors in Alzheimer cerebellum. Ann Neurol 1990;28:805-810.
82. Chalmers DT, Dewar D, Graham DI, Brooks DN, McCulloch J: Differential alterations of cortical glutamatergic binding sites in senile dementia of the Alzheimer type. Proc Natl Acad Sci USA 1990;87:1352-1356.
83. Geddes JW, Ulas J, Brunner LC, Choe W, Cotman CW: Hippocampal excitatory amino acid receptors in elderly, normal individuals and those with Alzheimer's disease: Non-N-methyl-D-aspartate receptors. Neuroscience 1992;50: 23-34.
84. Harrison PJ, Barton AJ, Najlerahim A, Pearson RC: Distribution of a kainate/AMPA receptor mRNA in normal and Alzheimer brain. Neuroreport 1990;1:149-152.
85. Pellegrini-Giampietro DE, Bennett MV, Zukin RS: AMPA/kainate receptor gene expression in normal and Alzheimer's disease hippocampus. Neuroscience 1994;61:41-49.
86. Ikonomovic MD, Mizukami K, Davies P, Hamilton R, Sheffield R, Armstrong DM: The loss of GluR2(3) immunoreactivity precedes neurofibrillary tangle formation in the entorhinal cortex and hippocampus of Alzheimer brains. J Neuropathol Exp Neurol 1997;56:1018-1027.
87. Aronica E, Dickson DW, Kress Y, Morrison JH, Zukin RS: Non-plaque dystrophic dendrites in Alzheimer hippocampus: A new pathological structure revealed by glutamate receptor immunocytochemistry. Neuroscience 1998;82:979-991.
88. Yasuda RP, Ikonomovic MD, Sheffield R, Rubin RT, Wolfe BB, Armstrong DM: Reduction of AMPA-selective glutamate receptor subunits in the entorhinal cortex of patients with Alzheimer's disease pathology: A biochemical study. Brain Res 1995;678:161-167.
89. Glazner GW, Chan SL, Lu C, Mattson MP: Caspase-mediated degradation of AMPA receptor subunits: A mechanism for preventing excitotoxic necrosis and ensuring apoptosis. J Neurosci 2000;20:3641-3649.
90. Chan SL, Griffin WS, Mattson MP: Evidence for caspase-mediated cleavage of AMPA receptor subunits in neuronal apoptosis and Alzheimer's disease. J Neurosci Res 1999;57:315-323.
91. Lu C, Fu W, Mattson MP: Caspase-mediated suppression of glutamate (AMPA) receptor channel activity in hippocampal neurons in response to DNA damage promotes apoptosis and prevents necrosis: Implications for neurological side effects of cancer therapy and neurodegenerative disorders. Neurobiol Dis 2001;8:194-206.
92. Lu C, Fu W, Salvesen GS, Mattson MP: Direct cleavage of AMPA receptor subunit GluR1 and suppression of AMPA currents by caspase-3: Implications for synaptic plasticity and excitotoxic neuronal death. Neuromolecular Med 2002;1:69-79.
93. Raina AK, Hochman A, Zhu X, et al: Abortive apoptosis in Alzheimer's disease. Acta Neuropathol (Berl) 2001;101:305-310.
94. 3H]Kainic acid binding and choline acetyltransferase activity in Alzheimer's dementia. Brain Res 1984;310:376-378.
95. Allen JW, Ivanova SA, Fan L, Espey MG, Basile AS, Faden AI: Group II metabotropic glutamate receptor activation attenuates traumatic neuronal injury and improves neurological recovery after traumatic brain injury. J Pharmacol Exp Ther 1999;290:112-120.
96. Matarredona ER, Santiago M, Venero JL, Cano J, Machado A: Group II metabotropic glutamate receptor activation protects striatal dopaminergic nerve terminals against MPP(+)-induced neurotoxicity along with brain-derived neurotrophic factor induction. J Neurochem 2001;76:351-360.
97. Copani A, Bruno V, Battaglia G, et al: Activation of metabotropic glutamate receptors protects cultured neurons against apoptosis induced by beta-amyloid peptide. Mol Pharmacol 1995;47:890-897.
98. Chiamulera C, Albertini P, Valerio E, Reggiani A: Activation of metabotropic receptors has a neuroprotective effect in a rodent model of focal ischaemia. Eur J Pharmacol 1992;216:335-336.
99. Miyamoto M, Ishida M, Shinozaki H: Anticonvulsive and neuroprotective actions of a potent agonist (DCG-IV) for group II metabotropic glutamate receptors against intraventricular kainate in the rat. Neuroscience 1997;77:131-140.
100. Buisson A, Choi DW: The inhibitory mGluR agonist, S-4-carboxy-3-hydroxy- phenylglycine selectively attenuates NMDA neurotox-icity and oxygen-glucose deprivation-induced neuronal death. Neuropharmacology 1995;34:1081-1087.
101. Buisson A, Yu SP, Choi DW: DCG-IV selectively attenuates rapidly triggered NMDA-induced neurotoxicity in cortical neurons. Eur J Neurosci 1996;8:138-143.
102. Battaglia G, Monn JA, Schoepp DD: In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats. Neurosci Lett 1997;229:161-164.
103. Kilbride J, Huang LQ, Rowan MJ, Anwyl R: Presynaptic inhibitory action of the group II metabotropic glutamate receptor agonists, LY354740 and DCG-IV. Eur J Pharmacol 1998;356:149-157.
104. Bruno V, Battaglia G, Casabona G, Copani A, Caciagli F, Nicoletti F: Neuroprotection by glial metabotropic glutamate receptors is mediated by transforming growth factor-beta. J Neurosci 1998;18:9594-9600.
105. Battaglia G, Bruno V, Pisani A, et al: Selective blockade of type-1 metabotropic glutamate receptors induces neuroprotection by enhancing gabaergic transmission. Mol Cell Neurosci 2001;17:1071-1083.
106. Bruno V, Battaglia G, Kingston A, et al: Neuroprotective activity of the potent and selective mGlu1a metabotropic glutamate receptor antagonist, (+)-2-methyl-4 carboxy-phenylglycine (LY367385): Comparison with LY357366, a broader spectrum antagonist with equal affinity for mGlu1a and mGlu5 receptors. Neuropharmacology 1999;38:199-207.
107. Pizzi M, Boroni F, Bianchetti KM, Memo M, Spano P: Reversal of glutamate excitotoxicity by activation of PKC-associated metabotropic glutamate receptors in cerebellar granule cells relies on NR2C subunit expression. Eur J Neurosci 1999;11:2489-2496.
108. Bruno V, Copani A, Knopfel T, et al: Activation of metabotropic glutamate receptors coupled to inositol phospholipid hydrolysis amplifies NMDA-induced neuronal degeneration in cultured cortical cells. Neuropharmacology 1995;34:1089-1098.
109. Pizzi M, Consolandi O, Memo M, Spano PF: Activation of multiple metabotropic glutamate receptor subtypes prevents NMDA-induced excitotoxicity in rat hippocampal slices. Eur J Neurosci 1996;8:1516-1521.
110. Bao WL, Williams AJ, Faden AI, Tortella FC: Selective mGluR5 receptor antagonist or agonist provides neuroprotection in a rat model of focal cerebral ischemia. Brain Res 2001;922:173-179.
111. O'Neill MJ: Pharmacology and neuroprotective actions of mGlu receptor ligands. Dev Med Child Neurol Suppl 2001;86:13-15.
112. Bruno V, Battaglia G, Copani A, et al: Activation of class II or III metabotropic glutamate receptors protects cultured cortical neurons against excitotoxic degeneration. Eur J Neurosci 1995;7:1906-1913.
113. Bruno V, Battaglia G, Ksiazek I, et al: Selective activation of mGlu4 metabotropic glutamate receptors is protective against excitotoxic neuronal death. J Neurosci 2000;20: 6413-6420.
114. Gasparini F, Bruno V, Battaglia G, et al: (R,S)-4-phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist, is anticonvulsive and neuroprotective in vivo. J Pharmacol Exp Ther 1999;289:1678-1687.
115. Faden AI, Ivanova SA, Yakovlev AG, Mukhin AG: Neuroprotective effects of group III mGluR in traumatic neuronal injury. J Neurotrauma 1997;14:885-895.
116. Laslo P, Lipski J, Funk GD: Differential expression of group I metabotropic glutamate receptors in motoneurons at low and high risk for degeneration in ALS. Neuroreport 2001;12:1903-1908.
117. Tomiyama M, Kimura T, Maeda T, et al: Expression of metabotropic glutamate receptor mRNAs in the human spinal cord: Implications for selective vulnerability of spinal motor neurons in amyotrophic lateral sclerosis. J Neurol Sci 2001;189:65-69.
118. Oka A, Takashima S: The up-regulation of metabotropic glutamate receptor 5 (mGluR5) in Down's syndrome brains. Acta Neuropathol (Berl) 1999;97:275-278.
119. Copani A, Bruno V, Battaglia G, et al: Activation of metabotropic glutamate receptors protects cultured neurons against apoptosis induced by beta-amyloid peptide. Mol Pharmacol 1995;47:890-897.
120. Lee RK, Wurtman RJ, Cox AJ, Nitsch RM: Amyloid precursor protein processing is stimulated by metabotropic glutamate receptors. Proc Natl Acad Sci USA 1995;92:8083-8087.
121. Lee RK, Jimenez J, Cox AJ, Wurtman RJ: Metabotropic glutamate receptors regulate APP processing in hippocampal neurons and cortical astrocytes derived from fetal rats. Ann NY Acad Sci 1996;777:338-343.
122. Lee RK, Wurtman RJ: Metabotropic glutamate receptors increase amyloid precursor protein processing in astrocytes: Inhibition by cyclic AMP. J Neurochem 1997;68:1830-1835.
123. Furukawa K, Sopher BL, Rydel RE, et al: Increased activity-regulating and neuroprotective efficacy of alpha-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain. J Neurochem 1996;67:1882-1896.
124. Smith-Swintosky VL, Pettigrew LC, Craddock SD, Culwell AR, Rydel RE, Mattson MP: Secreted forms of beta-amyloid precursor protein protect against ischemic brain injury. J Neurochem 1994;63:781-784.
125. Otani S, Auclair N, Desce JM, Roisin MP, Crepel F: Dopamine receptors and groups I and II mGluRs cooperate for long-term depression induction in rat prefrontal cortex through converging postsynaptic activation of MAP kinases. J Neurosci 1999;19:9788-9802.
126. Zhu X, Castellani RJ, Takeda A, et al: Differential activation of neuronal ERK, JNK/ SAPK and p38 in Alzheimer disease: The 'two hit' hypothesis. Mech Ageing Dev 2001;123:39-46.
127. Zhu X, Raina AK, Rottkamp CA, et al: Activation and redistribution of c-jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. J Neurochem 2001;76:435-441.
128. Zhu X, Rottkamp CA, Boux H, Takeda A, Perry G, Smith MA: Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. J Neuropathol Exp Neurol 2000;59: 880-888.